Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/cr960153y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fatuamide A, a Hybrid PKS/NRPS Metallophore from a sp. Marine Cyanobacterium Collected in American Samoa.
J Nat Prod
January 2025
Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, California 92093, United States.
A structurally novel metabolite, fatuamide A (), was discovered from a laboratory cultured strain of the marine cyanobacterium sp., collected from Faga'itua Bay, American Samoa. A bioassay-guided approach using NCI-H460 human lung cancer cells directed the isolation of fatuamide A, which was obtained from the most cytotoxic fraction.
View Article and Find Full Text PDFStrategies and Prospects for Engineering a Stable Zn Metal Battery: Cathode, Anode, and Electrolyte Perspectives.
Acc Chem Res
January 2025
Department of Chemistry, Shanghai Key Laboratory of Catalysis and Innovative Materials, Center of Chemistry for Energy Materials Shanghai, Fudan University, Shanghai 200433, PR China.
ConspectusZinc metal batteries (ZMBs) appear to be promising candidates to replace lithium-ion batteries owing to their higher safety and lower cost. Moreover, natural reserves of Zn are abundant, being approximately 300 times greater than those of Li. However, there are some typical issues impeding the wide application of ZMBs.
View Article and Find Full Text PDFNew PPARα Agonist A190-Loaded Microemulsion for Chemotherapy-Induced Peripheral Neuropathy.
Mol Pharm
January 2025
Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of anticancer agents with limited effective preventive or therapeutic interventions. Although fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPARα) agonist, has demonstrated neuroprotective and analgesic properties, its clinical utility is hindered by low receptor affinity, poor subtype selectivity, and suboptimal bioavailability. A190, a highly selective and potent nonfibrate PPARα agonist, offers a promising alternative but is limited by poor aqueous solubility, resulting in reduced oral bioavailability and therapeutic efficacy.
View Article and Find Full Text PDFLandau-Levich Scaling for Optimization of Quantum Dot Layer Morphology and Thickness in Quantum-Dot Light-Emitting Diodes.
ACS Nano
January 2025
Department of Chemical and Biomolecular Engineering, Lehigh University, 124 E. Morton Street, Bethlehem, Pennsylvania 18015, United States.
Quantum dot (QD) light-emitting diodes (QLEDs) are promising candidates for next-generation displays because of their high efficiency, brightness, broad color gamut, and solution-processability. Large-scale solution-processing of electroluminescent QLEDs poses significant challenges, particularly concerning the precise control of the active layer's thickness and uniformity. These obstacles directly impact charge transport, leading to current leakage and reduced overall efficiency.
View Article and Find Full Text PDFSubunit-specific conductance of single homomeric and heteromeric HCN pacemaker channels at femtosiemens resolution.
Proc Natl Acad Sci U S A
February 2025
Institut für Physiologie II, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena 07740, Germany.
In mammals, the four subunit isoforms HCN1-4 assemble to form functional homotetrameric and heterotetrameric hyperpolarization-activated cyclic nucleotide-modulated (HCN) ion channels. Despite the outstanding relevance of HCN channels for organisms, including generating electrical rhythmicity in cardiac pacemaker cells and diverse types of brain neurons, key channel properties are still elusive. In particular, the unitary conductance, of HCN channels is highly controversial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!